• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Novel biomarkers and emerging tools to identify causal molecular pathways in hypertension and associated cardiovascular diseases
Kardiol Pol. 2023 Feb 5. doi: 10.33963/KP.a2023.0037. Online ahead of print.ABSTRACTHypertension (HT) is a modifiable risk factor for life-threatening cardiovascular diseases (CVDs) including coronary artery disease, heart failure or stroke. Despite significant progress in understanding of the pathophysiological mechanisms of the disease, the molecular pathways targeted by HT treatment still remain largely unchanged. This warrants the necessity for searching novel biomarkers, which are causally related to persistent high blood pressure (BP) and may be pharmacologically targeted. Data from large-scale biobanks, containing h...
Source: Polish Heart Journal - February 5, 2023 Category: Cardiology Authors: Ewelina J ózefczuk Tomasz J Guzik Mateusz Siedlinski Source Type: research

Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease
Fertil Steril. 2022 May;117(5):924-935. doi: 10.1016/j.fertnstert.2022.03.009.ABSTRACTPolycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and is hallmarked by hyperandrogenism, oligo-ovulation, and polycystic ovarian morphology. Polycystic ovary syndrome, particularly the hyperandrogenism phenotype, is associated with several cardiometabolic abnormalities, including obesity, dyslipidemia, elevated blood pressure, and prediabetes or type 2 diabetes. Many, but not all, studies have suggested that PCOS is associated with increased risk of cardiovascular disease (CVD), includi...
Source: Atherosclerosis - May 5, 2022 Category: Cardiology Authors: Carolyn Guan Salman Zahid Anum S Minhas Pamela Ouyang Arthur Vaught Valerie L Baker Erin D Michos Source Type: research

Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (From the Treating to New Targets (TNT) and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trials)
The goal of this analysis was to evaluate the ability of insulin resistance, identified by the presence of prediabetes mellitus (PreDM) combined with either an elevated triglyceride (TG>1.7mmol/L) or body mass index (BMI> 27.0 kg/m2), to identify increased risk of statin-associated type 2 diabetes mellitus (T2DM). Consequently, a retrospective analysis of data from non-diabetic individuals in the TNT and SPARCL randomized controlled trials was performed, subdividing participants into 4 experimental groups: 1) normal fasting glucose (NFG) and TG ≤ 1.7 mmol/L (42%); 2) NFG and TG> 1.7 mmol/L (22%); 3) PreDM and TG ≤ 1.7 ...
Source: The American Journal of Cardiology - August 11, 2016 Category: Cardiology Authors: Payal Kohli, Joshua W. Knowles, Ashish Sarraju, David D. Waters, Gerald Reaven Source Type: research

Ten year experience of using a novel metabolic protocol in 'off pump' coronary artery bypass revascularization
Conclusions: Off-pump coronary artery bypass coupled with this novel metabolic protocol was associated with a low operative mortality and acceptable perioperative morbidities, including patients with left main coronary artery disease. These benefits are apparent at both short- and medium-term follow up.
Source: Therapeutic Advances in Cardiovascular Disease - November 16, 2015 Category: Cardiology Authors: Perkowski, D. J., Wagner, S., Muller, K., Schneider, J. R., St.Cyr, J. A. Tags: Original Research Source Type: research

Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.
CONCLUSION: Methotrexate at low doses, such those used for maintenance therapy of RA, predicted a decreased risk of CVE. Since methotrexate doesn't interfere with blood lipids, platelet aggregation or insulin resistance, the protective association may originate from mechanisms other than those exerted by antiplatelet drugs or statins. PMID: 25697810 [PubMed - as supplied by publisher]
Source: The Anatolian Journal of Cardiology - February 16, 2015 Category: Cardiology Authors: De Vecchis R, Baldi C, Palmisani L Tags: Anadolu Kardiyol Derg Source Type: research

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a 2-4x increased incidence of death from coronary artery disease. Patients with diabetes are considered for cardiovascular disease secondary prevention because their risk level is similar to that reported in patients without diabetes who have already suffered a myocardial infarction. More recently, with a better risk factors control, mainly in intensive LDL cholesterol target...
Source: Cardiovascular Diabetology - October 22, 2014 Category: Cardiology Authors: Francisco SaraivaAndrei Sposito Source Type: research

Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting
Conclusion Within a short period of 3–4 weeks, CR led to substantial improvements in key risk factors such as lipid profile, blood pressure, and physical fitness for all patients, even if CKD was present.
Source: European Journal of Preventive Cardiology - August 18, 2014 Category: Cardiology Authors: Voller, H., Gitt, A., Jannowitz, C., Karoff, M., Karmann, B., Pittrow, D., Reibis, R., Hildemann, S. Tags: Original scientific papers Source Type: research